BACKGROUND In recent years,immune checkpoint inhibitors(ICIs)have demonstrated remarkable efficacy across diverse malignancies.Notably,in patients with advanced gastric cancer,the use of programmed death 1(PD-1)blocka...BACKGROUND In recent years,immune checkpoint inhibitors(ICIs)have demonstrated remarkable efficacy across diverse malignancies.Notably,in patients with advanced gastric cancer,the use of programmed death 1(PD-1)blockade has significantly prolonged overall survival,marking a pivotal advancement comparable to the impact of Herceptin over the past two decades.While the therapeutic benefits of ICIs are evident,the increasing use of immunotherapy has led to an increase in immune-related adverse events.CASE SUMMARY This article presents the case of a patient with advanced gastric cancer and chronic plaque psoriasis.Following sintilimab therapy,the patient developed severe rashes accompanied by cytokine release syndrome(CRS).Fortunately,effective management was achieved through the administration of glucocorticoid,tocilizumab,and acitretin,which resulted in favorable outcomes.CONCLUSION Glucocorticoid and tocilizumab therapy was effective in managing CRS after PD-1 blockade therapy for gastric cancer in a patient with chronic plaque psoriasis.展开更多
Background:Rheumatoid arthritis(RA),a chronic autoimmune disease,has a high incidence and disability rate,causing patients significant discomfort.Although several medicines can be effective,they are also associated wi...Background:Rheumatoid arthritis(RA),a chronic autoimmune disease,has a high incidence and disability rate,causing patients significant discomfort.Although several medicines can be effective,they are also associated with significant adverse effects.In contrast,fumigation as one of the most often used traditional Chinese medicine(TCM)external therapy has shown both efficacy and safety with less side effect.In light of this,we comple-ment western medicine treatment with TCM fumigation therapy to improve patients’clinical efficacy,alleviate symptoms,and improve prognosis.Objective:To investigate the therapeutic effect of TCM fumigation and modern medicine combined therapy in treating RA patients with cold-dampness Bi syndrome.Methods:A single-center,randomized,controlled study was designed.From January 2022 to December 2022,a total of 60 RA patients with cold-dampness Bi syndrome were enrolled in the study.The control group(30 cases)received conventional modern medicine treatment with methotrexate for 4 weeks,while the observation group(30 cases)for 4 weeks received a combination of TCM fumigation treatment and conventional modern medicine.The effects of the two groups were comprehensively compared,including the changes in TCM symptom scores and laboratory indicators,as well as the use of visual analogue scale(VAS)and health status rating scale(HAQ)before and after treatment.Results:The total effective rate of the observation group was 93.3%,which was significantly higher than that of the control group,which is 70%(P<0.05).Before treatment,there were no significant differences in joint functional activity,pain visual analogue scale(VAS),health assessment questionnaire(HAQ-DI)and laboratory indexes between the two groups(P>0.05).After treatment,each group compared to their initial condition,respectively,showed major improvement of joint functional activity and significantly decreased VAS,HAQ-DI,and RA-related biomarkers(P<0.05);inter-group comparison of these indicators showed significanty further enhanced effect of TCM fumigation combined therapy on the RA-related biomarkers and joint functional activity of patients(P<0.05),yet the control group receiving only modern medicine showed better results of the VAS and HAQ-DI.Conclusion:The TCM fumigation combined therapy is effective to treat RA patients with cold-dampness Bi syn-drome,and to enhance their life quality,improving the joint function,and reducing inflammation.展开更多
目的研究急性脑梗死(Acute cerebral infarction,ACI)风痰瘀阻证患者血清神经元特异性烯醇化酶(Neuron specific enolase,NSE)对辨证分型及病情的评估价值。方法选取2018年4月—2020年4月期间北京中医药大学附属护国寺中医医院收治的AC...目的研究急性脑梗死(Acute cerebral infarction,ACI)风痰瘀阻证患者血清神经元特异性烯醇化酶(Neuron specific enolase,NSE)对辨证分型及病情的评估价值。方法选取2018年4月—2020年4月期间北京中医药大学附属护国寺中医医院收治的ACI患者作为研究对象,根据中医辨证分型将风痰瘀阻证患者纳入观察组、其他分型纳入对照组,检测NSE、中性粒细胞/淋巴细胞比值(Neutrophil-to-lymphocyte ratio,NLR)、同型半胱氨酸(Homocysteine,Hcy)、缺血修饰白蛋白(Ischemia modified albumin,IMA)、C反应蛋白(C-reactive protein,CRP),采用美国国立卫生院卒中量表(The National Institutes of Health Stroke Scale,NIHSS)、改良Rankin量表(Modified Rankin Scale,mRS)及中医证候积分评价病情,随访90 d预后。结果观察组患者的血清NSE含量高于对照组(P<0.05)且NSE对风痰瘀阻证具有诊断价值,临界值为;观察组中NSE含量≥16.40 ng/ml患者的NIHSS、mRS评分、中医证候积分及NLR、Hcy、IMA、CRP水平均高于NSE含量<16.40 ng/ml患者(P<0.05);观察组中预后不良患者的血清NSE含量高于预后良好患者(P<0.05),且NSE对预后具有预测价值。结论血清NSE对ACI风痰瘀阻证具有诊断价值,也可用于病情及预后的评估。展开更多
基金Supported by Shaoxing Health Science and Technology Program,No.2022SY016,No.2022KY010.
文摘BACKGROUND In recent years,immune checkpoint inhibitors(ICIs)have demonstrated remarkable efficacy across diverse malignancies.Notably,in patients with advanced gastric cancer,the use of programmed death 1(PD-1)blockade has significantly prolonged overall survival,marking a pivotal advancement comparable to the impact of Herceptin over the past two decades.While the therapeutic benefits of ICIs are evident,the increasing use of immunotherapy has led to an increase in immune-related adverse events.CASE SUMMARY This article presents the case of a patient with advanced gastric cancer and chronic plaque psoriasis.Following sintilimab therapy,the patient developed severe rashes accompanied by cytokine release syndrome(CRS).Fortunately,effective management was achieved through the administration of glucocorticoid,tocilizumab,and acitretin,which resulted in favorable outcomes.CONCLUSION Glucocorticoid and tocilizumab therapy was effective in managing CRS after PD-1 blockade therapy for gastric cancer in a patient with chronic plaque psoriasis.
基金This tudy was supported and funded by Science and Technology Project of Jiangxi Provincial Administration of Traditional Chinese Medicine(2021B117).
文摘Background:Rheumatoid arthritis(RA),a chronic autoimmune disease,has a high incidence and disability rate,causing patients significant discomfort.Although several medicines can be effective,they are also associated with significant adverse effects.In contrast,fumigation as one of the most often used traditional Chinese medicine(TCM)external therapy has shown both efficacy and safety with less side effect.In light of this,we comple-ment western medicine treatment with TCM fumigation therapy to improve patients’clinical efficacy,alleviate symptoms,and improve prognosis.Objective:To investigate the therapeutic effect of TCM fumigation and modern medicine combined therapy in treating RA patients with cold-dampness Bi syndrome.Methods:A single-center,randomized,controlled study was designed.From January 2022 to December 2022,a total of 60 RA patients with cold-dampness Bi syndrome were enrolled in the study.The control group(30 cases)received conventional modern medicine treatment with methotrexate for 4 weeks,while the observation group(30 cases)for 4 weeks received a combination of TCM fumigation treatment and conventional modern medicine.The effects of the two groups were comprehensively compared,including the changes in TCM symptom scores and laboratory indicators,as well as the use of visual analogue scale(VAS)and health status rating scale(HAQ)before and after treatment.Results:The total effective rate of the observation group was 93.3%,which was significantly higher than that of the control group,which is 70%(P<0.05).Before treatment,there were no significant differences in joint functional activity,pain visual analogue scale(VAS),health assessment questionnaire(HAQ-DI)and laboratory indexes between the two groups(P>0.05).After treatment,each group compared to their initial condition,respectively,showed major improvement of joint functional activity and significantly decreased VAS,HAQ-DI,and RA-related biomarkers(P<0.05);inter-group comparison of these indicators showed significanty further enhanced effect of TCM fumigation combined therapy on the RA-related biomarkers and joint functional activity of patients(P<0.05),yet the control group receiving only modern medicine showed better results of the VAS and HAQ-DI.Conclusion:The TCM fumigation combined therapy is effective to treat RA patients with cold-dampness Bi syn-drome,and to enhance their life quality,improving the joint function,and reducing inflammation.
文摘目的研究急性脑梗死(Acute cerebral infarction,ACI)风痰瘀阻证患者血清神经元特异性烯醇化酶(Neuron specific enolase,NSE)对辨证分型及病情的评估价值。方法选取2018年4月—2020年4月期间北京中医药大学附属护国寺中医医院收治的ACI患者作为研究对象,根据中医辨证分型将风痰瘀阻证患者纳入观察组、其他分型纳入对照组,检测NSE、中性粒细胞/淋巴细胞比值(Neutrophil-to-lymphocyte ratio,NLR)、同型半胱氨酸(Homocysteine,Hcy)、缺血修饰白蛋白(Ischemia modified albumin,IMA)、C反应蛋白(C-reactive protein,CRP),采用美国国立卫生院卒中量表(The National Institutes of Health Stroke Scale,NIHSS)、改良Rankin量表(Modified Rankin Scale,mRS)及中医证候积分评价病情,随访90 d预后。结果观察组患者的血清NSE含量高于对照组(P<0.05)且NSE对风痰瘀阻证具有诊断价值,临界值为;观察组中NSE含量≥16.40 ng/ml患者的NIHSS、mRS评分、中医证候积分及NLR、Hcy、IMA、CRP水平均高于NSE含量<16.40 ng/ml患者(P<0.05);观察组中预后不良患者的血清NSE含量高于预后良好患者(P<0.05),且NSE对预后具有预测价值。结论血清NSE对ACI风痰瘀阻证具有诊断价值,也可用于病情及预后的评估。
